These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 9014430)

  • 1. [Treatment and prognosis of juvenile parkinsonism--L-dopa responsiveness].
    Takubo H
    Nihon Rinsho; 1997 Jan; 55(1):101-5. PubMed ID: 9014430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
    Mazzella L; Yahr MD; Marinelli L; Huang N; Moshier E; Di Rocco A
    Parkinsonism Relat Disord; 2005 May; 11(3):151-5. PubMed ID: 15823479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Parkinson disease--problems in long-term treatment. Dopamine agonists optimize L-dopa therapy].
    Fuchs G
    Fortschr Med; 1997 Feb; 115(5):43-5. PubMed ID: 9162718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.
    Tomiyama M; Kimura T; Maeda T; Kannari K; Matsunaga M; Baba M
    Neurosci Res; 2005 Jun; 52(2):185-94. PubMed ID: 15893579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Medical treatment of L-dopa induced dyskinesia].
    Kuno S
    Nihon Rinsho; 2000 Oct; 58(10):2110-4. PubMed ID: 11068456
    [No Abstract]   [Full Text] [Related]  

  • 9. Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality.
    Schrag A; Ben-Shlomo Y; Brown R; Marsden CD; Quinn N
    Mov Disord; 1998 Nov; 13(6):885-94. PubMed ID: 9827611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Progress in diagnosis and treatment of juvenile parkinsonism].
    Ishikawa A
    Nihon Rinsho; 1993 Nov; 51(11):2947-51. PubMed ID: 7903987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F; Lilliu H; Le Pen C
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioids and motor complications in Parkinson's disease.
    Samadi P; Bédard PJ; Rouillard C
    Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
    Segovia G; Mora F; Crossman AR; Brotchie JM
    Mov Disord; 2003 Feb; 18(2):138-49. PubMed ID: 12539206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease.
    Priano L; Albani G; Calderoni S; Baudo S; Lopiano L; Rizzone M; Astolfi V; Cavalli R; Gasco MR; Fraschini F; Bergamasco B; Mauro A
    Neurol Sci; 2002 Sep; 23 Suppl 2():S99-100. PubMed ID: 12548362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe Parkinsonian's patients].
    Vaamonde J; Ibáñez R; Gudín M; Hernández A
    Neurologia; 2003 Apr; 18(3):162-5. PubMed ID: 12677484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.